Pandion Therapeutics bags USD 58 million in series A Funding
Focused on developing Targeted immune modulator drugs, Pandion Therapeutics has successfully grabbed USD 58 million in series A funding. The company is led by highly experienced professionals. Anthony Coyle (former senior vice president at Pfizer and global head of biologics at MedImmune) has signed on as CEO and Jo Viney (former head drug discovery and immunology research at Biogen) joined as the Chief scientific officer.
Carmot Therapeutics grabs USD 15 million for GLP-1R/GIPR agonist
In a recent funding, Carmot Therapeutics has successfully grabbed USD 15 million in series B, the company will further carry...